- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about NVCN
Recent news which mentions NVCN
From Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For January 18, 2023
January 18, 2023
From Benzinga
Nasdaq Edges Higher; Neovasc Shares Jump
January 17, 2023
From Benzinga
Why Calyxt Shares Are Trading Higher By Around 116%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
January 17, 2023
From Benzinga
Why Neovasc Shares Are Trading Higher Today
January 17, 2023
From Benzinga
Dow Tumbles 300 Points; Morgan Stanley Beats Q4 Views
January 17, 2023
From Benzinga
Dow Drops Over 150 Points; Goldman Sachs Profit Misses Expectations
January 17, 2023
From Benzinga
Shockwave Medical Seeks To Bolster Its Cardiovascular Disease Portfolio With Neovasc Acquisition
January 17, 2023
From Benzinga
Stocks That Hit 52-Week Lows On Friday
November 25, 2022
From Benzinga
Earnings Scheduled For August 11, 2022
August 11, 2022
From Benzinga
Earnings Scheduled For May 12, 2022
May 12, 2022
From Benzinga
Stocks That Hit 52-Week Highs On Monday
May 02, 2022
From Benzinga
74 Biggest Movers From Yesterday
April 29, 2022
From Benzinga
Earnings Scheduled For March 10, 2022
March 10, 2022
From Benzinga
The Week Ahead In Biotech (March 6-12): Quiet Week On Tap With Earnings Season Reaching It Final Leg
March 06, 2022
From Benzinga
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
November 09, 2021
From Benzinga
Neovasc Receives FDA Approval for COSIRA-II Clinical Trial
October 19, 2021
From Benzinga
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
October 08, 2021
From Benzinga
From Benzinga
The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts
August 10, 2021
From Benzinga
Earnings Scheduled For August 10, 2021
August 10, 2021
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.